SVB Wealth LLC Lowers Stake in Agilent Technologies, Inc. $A

SVB Wealth LLC lowered its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 42.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,905 shares of the medical research company’s stock after selling 23,981 shares during the period. SVB Wealth LLC’s holdings in Agilent Technologies were worth $3,732,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Whipplewood Advisors LLC lifted its holdings in shares of Agilent Technologies by 286.2% during the 1st quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 186 shares during the last quarter. Sunbelt Securities Inc. lifted its holdings in shares of Agilent Technologies by 640.0% during the 4th quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 192 shares during the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Agilent Technologies during the 1st quarter valued at $30,000. Opal Wealth Advisors LLC purchased a new stake in shares of Agilent Technologies during the 1st quarter valued at $31,000. Finally, Wood Tarver Financial Group LLC purchased a new stake in shares of Agilent Technologies during the 4th quarter valued at $34,000. Hedge funds and other institutional investors own 87.41% of the company’s stock.

Agilent Technologies Price Performance

Shares of A opened at $121.4920 on Friday. The business’s 50-day moving average is $117.88 and its two-hundred day moving average is $117.47. The company has a market capitalization of $34.51 billion, a P/E ratio of 30.00, a P/E/G ratio of 3.55 and a beta of 1.22. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.60 and a current ratio of 2.09. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.05. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%.The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.63 billion. During the same period last year, the firm earned $1.22 EPS. The firm’s revenue for the quarter was up 6.0% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. Research analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer directly owned 37,448 shares of the company’s stock, valued at $4,397,893.12. This represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.26% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. TD Cowen increased their price objective on Agilent Technologies to $150.00 and gave the company a “buy” rating in a report on Thursday, May 29th. Barclays upped their target price on Agilent Technologies from $115.00 to $125.00 and gave the company an “equal weight” rating in a research report on Tuesday, June 24th. Robert W. Baird cut their target price on Agilent Technologies from $159.00 to $140.00 and set an “outperform” rating on the stock in a research report on Thursday, May 22nd. Evercore ISI upped their target price on Agilent Technologies from $125.00 to $130.00 and gave the company an “in-line” rating in a research report on Tuesday, July 8th. Finally, UBS Group cut their target price on Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a research report on Thursday, May 29th. Seven investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Agilent Technologies has an average rating of “Moderate Buy” and a consensus target price of $139.77.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.